JBJaafar Bennouna

Jaafar Bennouna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaafar Bennouna has a total of 213 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

    by Thierry Andre, Franck Bonnetain, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Jérôme Dauba, Dewi Vernerey, Nasredine Aissat, Christophe Louvet, et al.

    3500 Background: The IDEA international collaboration was established to combine data from 6 randomized trials to assess whether a 3-month (3M) of oxaliplatin/fluoropyrimidines-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) for 3-year disease free survival (DFS) in stage III colon cancer (CC). Methods: French IDEA randomized patients (pts) between 3M and 6M of CT with mFOLFOX6 or XELOX (physician/pts choice). DFS was estimated using the Kaplan–Meier method and described using 3 years DFS rate. Results: Among 2022 randomized pts between May 2009 and May 2014, 2010 (99.4%) received CT and were enrolled in the mITT population: 49.9 and 50.1% in 3M and 6M, respectively. 99.5% of the mITT pts had stage III (N1: 74.9%; N2: 25.2%); median age 63.9 years; mFOLFOX6: 90% and XELOX 10% of pts. DFS median follow-up is 50.2 months. There were 578 DFS events (314 in 3M and 264 in 6M arm) leading to a 3-year DFS rate of 72.1% in the 3M vs. 75.7% in the 6M (HR=1.24; 95%CI 1.05–1.46, p=0.0112). For pts receiving mFOLFOX6, 3-year DFS rate was 72.0% in the 3M vs. 76.3% in the 6M (HR=1.27; 95%CI 1.07–1.51 p=0.0069). 94.2% and 78.0% of pts completed 3 and 6 months of CT, respectively. Median oxaliplatin doses intensity were 96.9% in 3M and 72.1% in 6M (495.0 and 735.1 mg/m2). By considering the neuropathy grade with 15375 neuropathy longitudinal measurements the overall maximal neuropathy grade 0-1/2/3-4 was 63.6/28.5/7.9% in 3M and 33.4/41.3/25.3% in 6M; p


  • Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).

    by Anthony Dohan, Benoit Gallix, Boris Guiu, Karine Le Malicot, Caroline Reinhold, Philippe Soyer, Jaafar Bennouna, Francois Ghiringhelli, Valerie Boige, Julien Taieb, et al.

    3601 Background: Quantitative assessment of tumor architecture changes may help to early identify non-responder patients and propose a tailored treatment strategy. Our objective was to build and validate a radiomics signature able to predict early the lack of response to chemotherapy including FOLFIFRI and bevacizumab using baseline and first evaluation CT and to compare it to the RECIST and morphological criteria. Methods: For 230 patients of PRODIGE 9 study and treated by FOLFIRI and bevacizumab, a computed analysis (CA) was performed on the dominant liver lesion (DLL) at baseline and 2 months post-chemotherapy. RECIST evaluation was performed at 2 and 6 months. The sum of the target liver lesions (STL), the density of the DLL, CA parameters and their changes rates were correlated with the 2-year survival status. A radiomics signature combining 3 parameters was built in one arm and validated in the second arm. Survival was estimated with the Kaplan-Meier method and compared with log-rank test. Results: The strongest predictive factors for 2-year survival status were decrease in STL(AUC = .69±.05[95%CI:.60-.77]), change rate in kurtosis(ssf = 0) (AUC = .66±.05[95%CI:.57-.74]), and the baseline density of the DLL (AUC = .68±.05[95%CI:.59-.77]). Using multivariate analysis, predictive factors of 2-year survival status were the decrease in STL > 15%(HR = 1.92, P= .002), the increase in kurtosis value(ssf = 0) > 93% (HR = 2.16, P= .001), and baseline DLL > 64.3UH (HR = 1.70, P= .02). Then, the SPECTRA-score was built by according 1 point for each of the 3 criteria. Patients with a SPECTRA-score > 1 had a lower overall survival in the training ( P= .001) and in the validation cohort ( P= .002). Non-response according to RECIST at 6 months had the same prognostic value as SPECTRA-score>1 at 2 months. Conclusions: A radiomics signature combining STL, density and CA on baseline and first evaluation CT is be able to predict which patient will have a poor outcome with same performances than standard evaluation with RECIST1.1 at 6 months in mCRC patients. Clinical trial information: NCT00952029.


  • Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial.

    by Fabrice Denis, Claire Lethrosne, Nicolas Pourel, Olivier Molinier, Yoann Pointreau, Julien Domont, Hugues Pierre Bourgeois, Helene Senellart, Pierre Tremolieres, Thibaut Lizee, et al.

    LBA9006 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 6, 2016, and in the Annual Meeting Proceedings online supplement to the June 20, 2016, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.


  • A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).

    by Helene Senellart, Emmanuelle Samalin, Florence Castan, Christophe Borg, Antoine Adenis, Christelle De La Fouchardiere, David Malka, Veronique Guerin-Meyer, Eric Francois, Meher Ben Abdelghani, et al.

    3537 Background: Promising results using cetuximab and erlotinib to treat wtKRAS metastatic colorectal cancer (mCRC) were reported by Weickhardt (J Clin Oncol 2012; 30:1505-12). Combining a monoclonal antibody and a tyrosine kinase inhibitor may be a treatment option for mCRC patients (pts). We investigated dual targeting with cetuximab and afatinib in chemotherapy refractory wtKRAS mCRC. Methods: wtKRAS mCRC pts (ECOG ≤ 1) who failed chemotherapy with irinotecan and oxaliplatin were eligible. Due to low accrual and the frequent use of an anti-EGFR antibody in the first- or second-line, the study was amended, after 19 inclusions, to allow pre-treatment with anti-EGFRs. This multicenter, prospective, open phase II trial randomized pts (2:1) to cetuximab (500mg/m2/two weeks) and oral afatinib (40mg/day) (Arm A) or cetuximab alone (500mg/m2/two weeks) (Arm B). Treatment continued until progression (evaluated every six weeks using RECIST 1.1) or limiting toxicity. At progression (Arm B) afatinib could be added to cetuximab. The primary objective was the non-progression rate at six months (Fleming’s one-step design, one-sided a = 5%, b = 10%, H0: 30%; H1: 50%; 75 pts needed, 49 in Arm A). Results: 75 pts were included between November 2012 and May 2015 in 14 French sites. We randomized 51 pts in Arm A and 24 in Arm B. The non-progression rate (CI95%) at six months was 17.0% in Arm A [7.7-30.8] and 20.8% in Arm B [7.1-42.2]. Median PFS (CI95%) and OS (CI95%) were 4.1 months [2.7; 5.4] and 13.6 months [7.7; 19.9] in Arm A; and 2.7 months [1.4; 4.7] and 13.4 months [4.7; 20.4] in Arm B. The objective response was 26.0% in Arm A and 8.3% in Arm B. 38 pts (76%) in Arm A vs 14 (58%) in Arm B had AEs of grade 3 or 4. Conclusions: ORR results are encouraging with cetuximab and afatinib. The median PFS has to be interpreted considering the criterion allowing pre-treatment with anti-EGFRs. Cross-over in Arm A could explain the similar median OS in both arms. Additional data will be presented (NRAS, subgroup of pts not pre-treated with anti-EGFRs, pts treated with cross-over). Clinical trial information: NCT01919879.


  • Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

    by Sandrine Hiret, Christophe Borg, Aurelie Bertaut, Olivier Bouche, Antoine Adenis, Gael Deplanque, Eric Francois, Thierry Conroy, Francois Ghiringhelli, Gaetan Des Guetz, et al.

    3514 Background: Second-line treatment with chemotherapy plus bevacizumab (Bev) or cetuximab (Cet) is now recognized as a standard treatment in mCRC. The main objective of this French multicenter, prospective open randomized trial was to evaluate the Progression Free Survival (PFS) rate at 4 months in patients receiving chemotherapy plus Bev or Cet after failure with Bev plus chemotherapy. Methods: The main eligibility criteria were disease progression after first-line chemotherapy: 5-FU with irinotecan or oxaliplatin associated with bevacizumab in wtKRAS mCRC. Patients were treated with cross over chemotherapy (FOLFIRI or mFOLFOX6) with bevacizumab (Arm A) or cetuximab (Arm B) until progression or limiting toxicity. The tumor response was evaluated every 6 weeks until progression using RECIST 1.1. Results: 133 patients, 86 male(64.7%), PS 0 (n = 74, 57.8%), 1 (n = 54, 42.2%), in 25 sites in France, were included between October 2010 and May 2015. Most frequent chemotherapy regimens delivered were mFOLFOX6 + Bev (n = 41) or Cet (n = 42); FOLFIRI + Bev (n = 25) or Cet (n = 25). The PFS rate at 4 months was 79% in Arm A and 66.7% in Arm B (p = 0.09). Secondary objectives included median PFS: 7.1 months (Arm A) vs 5.6 months (Arm B) (HR = 1.43; 95%CI [0.99-2.06] p = 0.06), and median OS: 15.9 months (Arm A) vs 10.6 months (Arm B) (HR = 1.44; 95%CI [0.95-2.18] p = 0.08). Conclusions: In wtKRAS mCRC patients progressing after bevacizumab plus chemotherapy, continuation beyond progression with bevacizumab and crossover chemotherapy is associated with a numerically higher but not statistically significant median PFS and OS compared to cetuximab plus chemotherapy. Final data with KRAS and NRAS analysis will be presented at the meeting. Clinical trial information: NCT01442649.


  • Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

    by Thomas Aparicio, Jaafar Bennouna, Karine Le Malicot, Francois Ghiringhelli, Valerie Boige, Julien Taieb, Olivier Bouche, Jean Marc Phelip, Eric Francois, Christian Borel, et al.

    3531 Background: Conflicting results are reported for maintenance treatment with bevacizumab (bev) during chemotherapy free intervals (CFI) in metastatic colorectal cancer (mCRC). Methods: The objective was to compare the tumor control duration (TCD) by either bev maintenance (Arm A) or no treatment during CFI (Arm B) after induction chemotherapy (CT) (12 cycles of FOLFIRI + bev). CT was reintroduced at progression (8 cycles) and then a new CFI. The randomization was performed before induction CT. TCD was defined by the time between randomization and tumor progression during a CT sequence (Aparicio T et al, Dig Liver Dis, 2015). Per Protocol (PP) population was defined as patients (pts) with at least one CT reintroduction after first progression during CFI. We present the final analysis of the trial. Results: From March 2010 to July 2013, 491 pts were randomized. The median age was 64.6 years [range: 27 - 89], 64% of the pts were men, 93% of the pts were OMS 0-1 and 218 (44%) pts had a non-resected primary tumor. A progression during induction CT happen in 85 (17%) pts, 261 (53%) pts had at least one reintroduction, 107 (22%) pts had two and 51 (10%) pts had three or more re-introductions. Multivariate analysis in all pts revealed that WHO performance status ≥ 2, unresected primary tumor and BRAF mutation were associated with a shorter TCD. Unresected primary tumor and BRAF mutation were associated with a shorter overall survival (OS). Grade 3-4 toxicities were observed in 80% of the pts in arm A and 79% in arm B. Conclusions: The alternate irinotecan-based CT sequences with or without bev maintenance during CFI, revealed an impressive TCD. Bev maintenance monotherapy did not improved TCD, progression free survival (PFS) or OS. Clinical trial information: NCT00952029.


  • Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO).

    by Simon Pernot, Cecile Badoual, Magali Terme, Florence Castan, Elie Marcheteau, Olivier Bouche, Jaafar Bennouna, Eric Francois, Francois Ghiringhelli, Christelle De La Fouchardiere, et al.

    4030 Background: Circulating tumor cells (CTC) with CellSearch Veridex, is a prognostic marker in breast, colon and prostate cancer approved by the Food and Drug Administration but is not validated in gastroesophageal adenocarcinomas (GEA). Objective: To evaluate the prognostic value of CTC in advanced GEA before and during treatment (Tx). Methods: 134 patients (pts) were enrolled in the biological substudy of the randomized trial PRODIGE 17 ACCORD 20 MEGA testing FOLFOX +/- panitumumab or rilotumumab in 1st-line Tx of locally advanced or metastatic GEA. Blood samples were collected on CellSave tubes on day (D)0 and D28, after 2 cycles. CTC were detected with CellSearch Veridex. Prognostic value of CTC was analyzed using the Cox model. Results: Quantification of CTC at D0 and D28 was achieved for respectively 106 and 65 pts. The median of CTC at D0 was 1 [range: 0-415], with 40 (38%), 17 (16%), 10 (9%), and 39 (37%) pts with 0, 1, 2, or > 2 CTC, respectively. A CTC level at D0 ≥ 2 was significantly associated with worse PFS and OS. The number of CTC decreased under Tx regardless of Tx arm (p < 0.001). The persistence of CTC ≥ 2 at D28 was associated with even poorer PFS and OS as compared to D0. After adjustment on tumor location, histological type (diffuse vs intestinal), age, ECOG PS and the number of metastases (1 vs > 1), CTC ≥ 2 at D0 remained an independent prognostic factor for PFS (HR: 1.71; 95%CI, 1.06-2.77; p = 0.03) and OS (HR: 2.03; 95%CI, 1.19-3.48; p = 0.01). No interaction was found between CTC and Tx received. Conclusions: Quantification of CTC before Tx could be a useful prognostic tool in advanced GEA. A CTC threshold ≥ 2 seems to have better discriminant value than the presence or absence of CTC. CTC quantitation at D28 may help to adapt Tx early in non-responding pts. Clinical trial information: NCT01443065.

  • Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial.

    by Antoine Adenis, Jaafar Bennouna, Pierre-Luc Etienne, Emilie Bogart, Eric Francois, Marie-Pierre Galais, Meher Ben Abdelghani, Nuria Kotecki, Pierre Michel, Jean-Philippe Metges, et al.

    4002 Background: Even though there is no evidence to support the use of CT in MSEC, many physicians treat pts with good ECOG performance status (PS) with fluorouracil (5FU)/platinum-based CT. Therefore, in order to estimate overall survival (OS) in MSEC, we designed a discontinuation phase 2 trial in pts free from progression (PD) after 6 weeks (wks) of CT. Methods: PS<3 MESC pts were treated with 1st-line 5FU/platinum-based CT, and underwent tumor assessment at 6 wks. Pts free from PD after 6 wks of CT were randomized (1:1) to receive CT continuation (arm A) or CT discontinuation plus BSC (arm B). In arm B, pts were allowed to restart CT in case of PD. Primary endpoint was ITT 9-month OS rate (calculated from randomization date). The sample size has been calculated to provide an estimate of ITT 9-month OS rate ± 12.5% in arm A. Arm B served as an internal control, without formal comparison intent.With an anticipated 58% dropout rate at 1st tumor assessment, 106 pts were needed to randomize 62 pts. Secondary objectives were tolerance, PFS, quality of life, and medical costs. Results: 105 pts were included, and 101 received CT (FOLFOX: 76/101; LV5FU2-CDDPq2w: 18/101; TPF: 4/101, FU-CDDPq3w: 3/101). 67/101 pts free from PD at 6 wks were randomized. Baseline pts characteristics were as follows: median age: 64; male gender: 54/67; PS ≤1/2: 61/6; number of metastatic sites 1/≥2: 31/36; BMI<18.5kg/m²: 6/67; prior exposure to CT (combined to radiation therapy and/or surgery): 37/67. 64/67 pts were eligible and treated (arm A 31, arm B 33). CTs were LV5FU2-CDDPq2w 7/31, FOLFOX 24/31. ITT 9-months OS rate was 50% (85%-CI: 37-62) for arm A and 44% (85%-CI: 31-56) for arm B. PFS after randomization was 2.8 mo (95% CI: 1.7-5) for arm A, and 1.4 mo (95% CI: 1.4-2.7) for arm B. Tolerance was good, as expected with the CT we used. Conclusions: Inpts with MESC free from PD after 6 wks of 5FU/platinum-based CT who were randomized to the CT-continuation arm, 9-month OS rate in arm A was 50%. Despite a trend in OS and PFS favoring arm A, it does not appear that CT continuation provides much clinical benefit over CT discontinuation plus BSC, in such pts. Results of quality of life and medical costs are awaited. Clinical trial information: NCT01248299.


  • Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

    by Camille Sibertin-Blanc, Aurelie Fabre, Thomas Aparicio, Karine Le Malicot, Jaafar Bennouna, Francois Ghiringhelli, Julien Taïeb, Valerie Boige, Olivier Bouche, Roger Faroux, et al.

    3534 Background: Bevacizumab (Bev) is widely used in mCRC but there is no validated predictive factor. Several studies have reported the impact of SNPs in the Vascular Endothelial Growth Factor-A (VEGF-A) pathway genes on the Bev’s efficacy but results in the mCRC are yet inconstant. PRODIGE 9 is a phase III trial that compare the tumor control duration (TCD) under a 1st-line chemotherapy followed by either Bev maintenance (Arm A) or no treatment during chemotherapy-free intervals (CFI) (Arm B).The aim of our study was to evaluate the impact of genetic polymorphisms of VEGF A, VEGFR1, VEGFR2 and HIF1α on TCD, duration of 1stCFI, progression-free survival (PFS) and overall survival (OS). Methods: We included patients (pts) of the PRODIGE 9 study for whom biological consent was signed and a DNA sample was available. Ten polymorphisms were genotyped on germ line DNA using real-time Polymerase Chain Reaction. DNA was extracted from blood samples. Survival analyses were done using Kaplan-Meier method and Cox model. For tRR, a logistic regression was used. Results: Among the 491 pts randomized in PRODIGE 9, DNA was available for 314 pts: 160 in Arm A and 154 in Arm B . The median TCD, OS and PFS, were respectively 15.7, 22.6 and 9.2 months (m). For VEGFR-1 rs9582036, pts with CC genotype had significantly better TCD (median [95%CI] 22.4 m [14.7- NR]) compared to pts with AA and CA genotypes (14.4 m [11.7-17.1] (p = 0.04)) in arm A whereas there was no difference in the other arm. This tendency was observed also for the 1st CFI (median 4.6 m for pts CC vs 4.1 m for AC and AA), for the median OS (28.2 vs 22.5 m), the RR, but it was not statistically significant (table). Conclusions: In this prospective study, VEGFR-1 rs9582036 variants were associated with clinical outcome in terms of TCD for patients with mCRC treated by Bev-based therapy. Clinical trial information: NCT00952029.


  • The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

    by Thierry Andre, Aimery De Gramont, Laurent Mineur, Jérôme Desramé, Roger Faroux, Jaafar Bennouna, Jérôme Dauba, Christophe Louvet, Simon Pernot, Olivier Jean Marie Dupuis, et al.

    633 Background: The IDEA international collaboration was established to prospectively combine/analyze data from six randomized trials to assess whether a 3-month course of oxaliplatin/fluoropyrimidines-based adjuvant chemotherapy (CT) is non-inferior to the 6-month current standard treatment in stage III colon cancer (CC). The primary endpoint of IDEA was 3-year disease-free survival. The accrual goal for the French IDEA study was 2,000 patients. Methods: French IDEA randomized patients with stage III CC between 3 months (arm A) and 6 months (arm B) of adjuvant CT with modified (m) FOLFOX6 or XELOX (depending on physician/patient choice). Oxaliplatin was stopped in case of persistent neuropathy grade ≥2 with fluoropyrimidines continuation for the planned duration. Toxicity was graded during treatment and follow-up using NCI-CTCAE v3.0. Results: From May 2009 to May 2014, 2,023 patients were randomized in 129 French centers either to arm A (n=1009, 49.9%) or to arm B (n=1014, 50.1%). 2012 (99.5%) patients had stage III disease (N1: 75%; N2: 25%) and 11 patients had stage II (n=2) or stage IV disease (n=9). Median age was 64 years (18-85). 89.4% of patients received mFOLFOX6, 10.1% of patients received XELOX, and 0.5% of patients did not receive any study treatment. Overall, 94.1% and 77.5% of patients completed 3 months (arm A) and 6 months (arm B) of CT, respectively. Median oxaliplatin dose was 500 mg/m2 in arm A and 747 mg/m2in arm B. Toxicity profiles depended on the FU backbone with more grade 3/4 neutropenia on mFOLFOX6 (15.0% vs 6.5%) and more grade 3/4 diarrhea (4.7% vs 8.1%) on XELOX. Grade 2/3-4 peripheral neuropathy was less common in arm A than in arm B (23.2/6% vs 37.9/20.4%). Grade 2/3-4 residual neuropathy for patients with a follow-up of at least 3 years (n=811, median follow-up of 3.91 years) was 2.3/0.5% in arm A vs 3.9/ 2.4% in arm B. At 6 months after randomization, mortality rate was 0.7% (n=7) on arm A and 0.5% (n=5) on arm B. Median follow-up is 2.74 years for the whole population. Conclusions: Both mFOLFOX6 and XELOX were safe. Peripheral neuropathy was lower in arm A than in arm B. Clinical trial information: 2009-010384-16.